Histone H3 lysine 4 methyltransferases and demethylases in self-renewal anddifferentiation of stem cells by unknown
Cell & Bioscience
Gu and Lee Cell & Bioscience 2013, 3:39
http://www.cellandbioscience.com/content/3/1/39REVIEW Open AccessHistone H3 lysine 4 methyltransferases and
demethylases in self-renewal and differentiation
of stem cells
Bingnan Gu and Min Gyu Lee*Abstract
Epigenetic mechanisms are fundamental to understanding the regulatory networks of gene expression that govern
stem cell maintenance and differentiation. Methylated histone H3 lysine 4 (H3K4) has emerged as a key epigenetic
signal for gene transcription; it is dynamically modulated by several specific H3K4 methyltransferases and
demethylases. Recent studies have described new epigenetic mechanisms by which H3K4 methylation modifiers
control self-renewal and lineage commitments of stem cells. Such advances in stem cell biology would have a
high impact on the research fields of cancer stem cell and regenerative medicine. In this review, we discuss the
recent progress in understanding the roles of H3K4 methylation modifiers in regulating embryonic and adult stem
cells’ fates.
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Stem cells have long-term self-renewing activity and can
commit to multiple cell types upon differentiation
signals. Since Yamanaka and colleagues demonstrated
that the four DNA-binding transcription factors Oct4,
Sox2, c-Myc, and Klf4 transform fibroblasts into a type
of pluripotent cells known as induced pluripotent stem
cells, the importance of transcription factors in cellular
reprogramming has been more recognized [1]. However,
because the reprogramming efficiency of these four
factors is low, it is evident that additional layers of co-
regulatory mechanisms exist besides transcription factor-
driven regulation [2]. In fact, a recent study demonstrated
that the histone modification and DNA methylation
profiles differ in one-third of the genome between human
embryonic stem (ES) cells and primary fibroblasts [3],
indicating that such remarkable epigenetic difference may
serve as a major molecular mechanism in determining
cellular characteristics of these two cell types. Notably, the
functions of epigenetic modifiers in stem cell fate decision
have been intensively studied.* Correspondence: mglee@mdanderson.org
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reproduction in any medium, provided the orHistone lysine methylation has been widely accepted
as a key epigenetic modification. Unlike acetylation, the
methylation does not change the charge of lysine resi-
dues and thus has a minimal direct effect on DNA-
histone association. Rather, the different methylation
status of specific histone lysines can serve as a unique
platform for recruiting methylation “reader” proteins
that activate or repress genes’ transcriptional activity. In
general, histone H3 lysine 4 (H3K4), H3K36, and H3K79
methylation are gene activation marks, whereas H3K9,
H3K27, and H4K20 methylation are gene-repressive
modifications [4].
Histone lysine methylation is generated by a battery of
histone methyltransferases (HMTs) that transfer the me-
thyl group from S-adenosylmethionine to specific lysine
residues. For example, H3K4 methylation is mediated by
several SET [Su(var)3-9, Enhancer of zeste, Trithorax]
domain-containing methyltransferases, including mixed
lineage leukemia 1–5 (MLL1−5), SET1A/B, SET7/9, SET
and MYND domain-containing protein 1–3 (SMYD1−3),
Absent, Small, or Homeotic 1-like (ASH1L), SET domain
and Mariner transposase fusion gene (SETMAR), and PR
domain zinc finger protein 9 (PRDM9) [5-24]. Methylated
lysines exist in three forms: mono-, di- and tri-methylation
(me1, me2, and me3).td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Gu and Lee Cell & Bioscience 2013, 3:39 Page 2 of 14
http://www.cellandbioscience.com/content/3/1/39Similar to other histone modifications, histone methy-
lation can be reversed by histone demethylases (HDMs).
The first identified lysine-specific demethylase 1 [LSD1;
also known as FAD-binding protein BRAF35-HDAC
complex, 110 kDa subunit (BHC110) and Lysine-specific
demethylase 1A (KDM1A)], together with LSD2, belongs
to the polyamine oxidase family. LSD1 and LSD2
remove methyl groups from di- and monomethylated
H3K4 but are unable to demethylate trimethylated
H3K4 [25-28]. LSD1 was reported to also have H3K9
demethylation activity [29]. Subsequently, many Jumonji
(JmjC) domain-containing histone demethylases have
been discovered. In particular, the JARID1 family of
histone demethylases (JARID1A−D) can erase H3K4me3
and H3K4me2 [30-35].
In this review, we summarize the recent progress in
understanding the functions of H3K4 methyltransferases
and demethylases in modulating stem cells’ fates.
H3K4 methylation
H3K4me3 occupies as many as 75% of all human gene
promoters in several cell types (e.g., ES cells), indicating
that it plays a critical role in mammalian gene expression
[36,37]. In fact, H3K4me3 is required to induce critical
developmental genes in animals, including Drosophila and
several mammals, and is important for animal embryonic
development [38]. H3K4me3 levels are positively corre-
lated with gene expression levels [39,40] (Figure 1A).
Although H3K4me3 is clearly associated with actively
transcribed genes, however, studies have demonstrated
that H3K4me3 is localized around the transcription initi-
ation sites of numerous unexpressed genes in human ES
cells, primary hepatocytes, and several other cell types
[36,37,41]. In particular, it frequently co-resides with the
repressive mark H3K27me3 in the promoters of critical
differentiation-specific genes [e.g., Homeobox (HOX)
gene clusters] that are transcriptionally inactive in ES
cells [36,37,42,43] (Figure 1B). It has been proposed that
the “bivalent” domains, composed of H3K4me3 and
H3K27me3, may maintain differentiation-specific gene
promoters in a repressive status in self-renewing stem
cells but be poised for prompt gene activation upon
differentiation stimuli [42]. Consistent with this, many
bivalent genes have increased H3K4me3 levels and de-
creased H3K27me3 levels while being transcriptionally
activated during differentiation. Interestingly, recent
studies demonstrated that most bivalent domains are
occupied by LSD1 [44,45], indicating that it plays a role in
maintaining low levels of dimethylated H3K4 (H3K4me2)
that are often co-localized with H3K4me3. For these
reasons, H3K4me3 is classified as a chromatin landmark
for transcriptionally active or poised genes in ES cells [41].
Compared with mouse thymocytes, mouse ES cells
contain higher levels of total genomic H3K4me3 andhave higher H3K4me3 occupancy at the promoter of the
pluripotent gene Oct4 [46]. In agreement with this, glo-
bal decreases in H3K4me3 levels occur during retinoic
acid (RA)-induced differentiation of mouse ES cells [47].
In addition, there are dynamic changes in H3K4me3
profiles at specific sets of genes during ES cell differenti-
ation. Such global and local changes in H3K4me3 pro-
files are partly because levels of H3K4me3-regulatory
factors [e.g., WD repeat-containing protein 5 (WDR5),
MLL1 and MLL3] are modulated [47]. It is believed that
higher H3K4me3 levels allow the ES cell genome to be
more open and transcriptionally permissive by recruiting
chromatin-modifying factors. Therefore, unique H3K4me3
profiles at pluripotent and differentiation-specific genes
may be key determinants of cellular identity.
Most H3K4me3-containing promoters are also occupied
by H3K9/H3K14 acetylation [41]. In transcriptionally
active genes, H3K36me3 and H3K79me2 are significantly
enriched downstream of H3K4me3-containing promoters:
H3K36me3 peaks toward the 3′ end of genes in gene bod-
ies, whereas H3K79me2 is located toward the 5′ end [41].
Therefore, H3K4me3 likely cooperates with other histone
marks for gene activation. The combinatorial arrangement
of H3K4me3 and other histone marks may support, at
least in part, the “histone code” hypothesis [48].
H3K4me2 decorates genomic regions independently of
H3K4me3, although most of it overlaps with H3K4me3
near the transcription start sites [49]. H3K4me2 may
have an antagonistic effect on DNA methylation [50].
Monomethylated H3K4 (H3K4me1) also co-occupies
regions near the start sites with H3K4me3. Apart
from the transcription start sites, H3K4me1, together
with H3K27 acetylation, specifies enhancer regions
[51,52]. In summary, H3K4me1, H3K4me2 and H3K4me3
have a commonality for gene activation, although their
subsets play distinct roles in modulating chromatin
function.
H3K4 methyltransferases
Some H3K4 methyltransferases are well conserved in
different species. In yeast, the Set1 complex, also called
Complex of Proteins Associated with Set1 (COMPASS),
catalyzes the mono-, di- and trimethylation of H3K4
[5,8]. The protein complex is composed of the catalytic
component of Set1 and seven other regulatory subunits
(Cps60, Cps50, Cps40, Cps35, Cps30, Cps25, and Cps15)
that are essential for full enzyme activity [38] (Table 1).
In Drosophila, there are three Set1 homologs: dSet1,
Trithorax (Trx), and Trithorax-related (Trr). The dele-
tion of any of their genes results in lethality in flies, indi-
cating that their target genes may not be redundant. In
particular, loss of dSet1, but not Trx or Trr, leads to a
global reduction of H3K4me2/3, suggesting that Trx and
Trr have more specialized functions [38]. Human
Figure 1 H3K4me3 marks actively transcribed and poised gene promoters in mammals. (A) The genome-wide correlation of mRNA
expression levels (High, Medium, Low, and Silent) with H3K4me3 levels at human gene promoters. Note that a dip of H3K4me3 levels may be
associated with the nucleosome-free region around the transcriptional start site (TSS). Adapted from [39]. (B) The Venn diagram showing the
percentage of genes that have H3K4me3 and/or H3K27me3 in their promoters in mouse and human ES cells. All percentages are based on about
total 18,000 genes. The “bivalent” denotes the promoters that contain both H3K4me3 and H3K27me3 marks. Adapted from [36,37,43].
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and are related to dSet1 (the counterpart of SET1A and
SET1B), Trx (the counterpart of MLL1 and MLL2), and
Trr (the counterpart of MLL3 and MLL4) in Drosophila.
Other SET domain-containing histone methyltransferases
that methylate H3K4 but are not closely related to yeast
Set1/COMPASS have also been identified and include
MLL5, SET7 (also called SET9), SMYD1-3, SETMAR, and
PRDM9 [6,15,24].
SET1A/1B and MLL1−4 are present in multi-protein
complexes and share common core subunits, such as
WDR5, Retinoblastoma-binding protein 5 (RBBP5),
ASH2L, and Dumpy-30 (DPY-30), which are also highlyconserved in yeast and flies [38] (Table 1). Several studies
have demonstrated that these core subunits are indispens-
able for the enzyme activity of methyltransferases and bio-
logical functions [53-55]. In addition to common core
subunits, there are unique subunits in the individual
H3K4 methyltransferase complexes: WDR82 and CXXC
finger protein 1 (CFP1) in the SET1 complex; Multiple
endocrine neoplasia type 1 (MENIN) and PC4 and SFRS1-
interacting protein 1 (PSIP1) in MLL1 and 2 complex;
Host cell factor 1/2 (HCF1/2) in SET1, MLL1, and MLL2
complexes; and PAX transcription activation domain
interacting protein 1 (PTIP), PTIP-associated protein 1
(PA1), Nuclear receptor coactivator 6 (NCOA6), and
Table 1 Subunit composition of H3K4 methyltransferase complexes in yeast and human
Yeast SET1 Human SET1A Human SET1B Human MLL1 Human MLL2 Human MLL3 Human MLL4 Human MLL5*
SET1 SET1A SET1B MLL1 MLL2 MLL3 MLL4 Mll5
Cps60/Bre2 ASH2L ASH2L ASH2L ASH2L ASH2L ASH2L HCF1
Cps50/Swd1 RBBP5 RBBP5 RBBP5 RBBP5 RBBP5 RBBP5 OGT
Cps30/Swd3 WDR5 WDR5 WDR5 WDR5 WDR5 WDR5 STK38
Cpd25/Sdc1 DPY-30 DPY-30 DPY-30 DPY-30 DPY-30 DPY-30 PPP1CA
Cps40/Spp1 CFP1 CFP1 PPP1CB
Cps35/Swd2 WDR82 WDR82 PPP1CC
Cps15/Shg1 BOD1/BOD1L ACTB
HCF1/2 HCF1/2 HCF1/2 HCF1/2 NCOA6 NCOA6
MENIN MENIN UTX UTX
PSIP1 PTIP PTIP
PA1 PA1
* The subunits of MLL5 are not related to those of SET1, SET1A/B, and MLL1−4.
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repeat protein (UTX) in the MLL3 and MLL4 complexes
[12,16,19,22,56-63] (Table 1). These subunits may play
important roles in recruiting H3K4 methyltransferases
to specific genes and integrating additional histone-
modifying capacities (see below).
MLL1 and MLL2
MLL1 (also known as MLL and KMT2A) was initially
cloned from acute myeloid and lymphoid leukemia that
contain frequent MLL1 chromosomal fusions and trans-
locations [64-66]. The MLL1 gene encodes a protein of
3,972 amino acids; this protein contains several highly
conserved functional domains, including the N-terminal
AT-hook DNA binding domains, Plant homeo domains
(PHD), a Bromo domain, and the catalytic SET domain
(Figure 2). Inside cells, MLL1 protein is cleaved into
MLL-N (320 kDa) and MLL-C (180 kDa) by Taspase I;
these two large fragments dimerize through FY-rich mo-
tifs to form the functional MLL complex in vivo [67,68].
Homozygous deletion of Mll1 is embryonic lethal;
Mll1+/− mice display retarded growth and hematopoietic
defects [69,70]. Specifically, expression of the key develop-
mental genes, including Hoxa7 and Hoxc9, were shifted
from the anterior boundaries toward the posterior regions
in Mll1+/− embryos and were lost in Mll1−/− mice [69]. In
addition, recent studies using a tissue-specific knockout
mouse model revealed that Mll1 is essential for sustaining
adult hematopoiesis [71,72]. Mll1 is not required for sur-
vival, proliferation, and differentiation of subventricular
zone neural stem cells but plays an essential role in
neurogenesis in the postnatal mouse brain [73]. Mechanis-
tically, Mll1 directly occupies the promoter of Distal-less
homeobox 2 (Dlx2), a critical regulator of neurogenesis,
and is required to resolve the poised bivalent state to the
actively transcribed status with predominant H3K4me3
during neurogenesis of neural stem cells [73].MLL2 (also called MLL4 and KMT2B) has a similar
protein domain structure to that of MLL1 and was
found to be the MLL1 paralog [74]. Like Mll1, Mll2 is
widely expressed during development and in adult tis-
sues. Mll2-null mice die before embryonic day E11.5,
with drastically reduced expression of Hoxb2 and Hoxb5
[75]. However, Mll2 may be only required briefly for de-
velopment, because it appears to be dispensable for
mouse development after E11.5 [76]. Mll2−/− ES cells
maintain pluripotency, have increased apoptotic activity,
and undergo skewed cellular differentiation along three
germ layers [77]. Therefore, Mll1 and Mll2 are unlikely
redundant for gene regulation during early embryonic
development. In support with this notion, the pheno-
types of Mll1 and Mll2 knockout mice are different in
adult tissues. For example, hematopoietic-specific loss of
Mll1 showed defects in hematopoiesis [71,72], whereas
Mll2 loss did not show any aberrant blood profiles and
notable pathology [76].
MLL3 and MLL4
MLL3 (also called HALR/KMT2C) and MLL4 (alias
ALR/KMT2D) are mammalian counterparts of Drosophila
Trr and were co-purified as transcriptional coactivator
complexes [14,78-80]. MLL3 and MLL4 associate with nu-
clear hormone receptors in both Drosophila and mam-
mals. For example, the MLL3/MLL4 complex is recruited
to HOXC6 gene and activates its transcription in an estro-
gen receptor-dependent manner [79]. Frequent somatic
loss-of-function mutations have been identified in MLL3
and MLL4 genes in human cancers, including colorectal
cancer, non-Hodgkin B-cell lymphoma, and medulloblas-
toma [81-85]. Consistently, a recent study reported that
trr gene product suppresses cell growth in Drosophila eye
imaginal discs. Of interest, trr mutation markedly reduced
H3K4 monomethylation levels without significantly chan-
ging H3K4 di- and trimethylation levels [86], in agreement
Figure 2 Protein domain architectures and stem cell function of MLL/SET1 H3K4 methyltransferases. AT: AT-hook DNA binding domain;
PHD: Plant Homeo Domain; BRD: Bromodomain; FYR: FY-rich domain; SET: Su(var)3-9, Enhancer of zeste, Trithorax domain; HMG: High Mobility
Group domain; RRM: RNA Recognition Motif.
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methyltransferase for Drosophila enhancers [87]. Mll3
homozygous mutant mice, which have an in-frame dele-
tion of a 61-aa catalytic core of the SET domain, exhibited
reduced white adipose tissue, stunted growth, and slow
cellular doubling rate [88,89]. During epidermal differenti-
ation, the MLL4 complex is recruited to differentiation-
related genes via the transcription factor GRHL3/GET1
and collaboratively activates the epidermal progenitor dif-
ferentiation program [90].
Recently, we found that MLL4 is essential for the
neuronal differentiation of human NT2/D1 stem cells
[91]. Mechanistically, the neuron-specific gene NESTIN
and key developmental genes HOXA1–3 are activated by
MLL4 during RA-induced differentiation. Intriguingly,
the tandem PHD4-6 of seven PHD motifs in MLL4
(Figure 2) specifically recognized unmethylated or asym-
metrically dimethylated histone H4 Arg 3 (H4R3me0 or
H4R3me2a) and is required for MLL4′s nucleosomal
methyltransferase activity and MLL4-mediated differenti-
ation. H4R3 symmetric dimethylation (H4R3me2s), agene-repressive mark, blocks the binding activity of
MLL4′s PHD4-6. Consistent with this, knockdown of the
protein arginine methyltransferase 7, which is involved in
generation of H4R3me2s, increases MLL4 occupancy and
H3K4me3 levels at the MLL4 target gene promoters and
enhances the MLL4-dependent neural differentiation pro-
gram. Therefore, these results revealed that the trans-tail
regulation of MLL4-catalyzed H3K4me3 by protein argin-
ine methyltransferase 7-controlled H4R3me2s serves as a
novel epigenetic mechanism underlying neuronal differen-
tiation of human stem cells.
MLL5
Independent studies have demonstrated that MLL5 is re-
quired for hematopoiesis [92-94]. Moreover, MLL5 pro-
motes myogenic differentiation by controlling expression
of cell cycle genes (e.g., Cyclin A2) and myogentic regu-
lator genes (e.g., Myogenin) [95]. Mll5 knockout male
mice are sterile, at least in part because of deregulated
expression of genes that are required for terminal differen-
tiation during spermatogenesis [96]. Of interest, although
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of MLL5 greatly increased MLL5′s enzymatic activity to-
wards H3K4me1/2 and facilitated RA-induced granulo-
poiesis in human HL60 promyelocytes [24].
SET1A and SET1B
Human SET1A and SET1B have an N-terminal RNA
recognition motif and a C-terminal enzymatic SET do-
main (Figure 2). The SET1A complex was purified as a
multi-protein complex that associates with CFP1 [19].
CFP1 is required for stem cell differentiation and inter-
acts with unmethylated CpGs via its zinc finger domain
CXXC [97]. Interestingly, Cfp1−/− ES cells displayed
aberrant H3K4me3 peaks at numerous ectopic sites
(i.e., distinct regions outside annotated CpG islands),
suggesting that CFP1 recruits the SET1 complex to
CpG island-containing promoters and consequently
prevents it from generating H3K4me3 to inappropriate
chromatin locations [19,98,99].
A protein sequence analysis revealed that SET1A
shares 39% identity with a SET domain protein named
SET1B [22]. Although both proteins associate with a
similar set of non-catalytic subunits, a confocal micros-
copy analysis revealed that SET1A and SET1B exhibit
distinct subnuclear localizations in euchromatin regions;
thus, this suggests that each protein regulates a unique
group of target genes [22].
ASH1L
ASH1L (also called Ash1) is the human homolog of
Ash1, a Drosophila Trithorax group protein that is es-
sential for expression of several HOX genes. Some re-
ports have indicated that ASH1L primarily acts as a
H3K4 methyltransferase [13,100,101], whereas others
have reported that human ASH1L specifically mono- and
dimethylates H3K36 [102-104]. ASH1L cooperates with
MLL1 in HOX gene activation and is required for the
myelomonocytic lineage differentiation of hematopoietic
stem cells [105]. Of interest, a mutation of the SET
domain of ASH1L did not decrease HOX gene expression,
suggesting that ASH1L’s catalytic activity is dispensable for
hematopoietic stem cell differentiation [105].
SET7/9
SET7 (or called SET9) is an H3K4 mono- and di-
methytransferase [6,106-108]. SET7 expression is upregu-
lated during myoblast differentiation [109]. Specifically,
SET7 interacts with Myoblast determination protein 1
(MyoD), a central transcriptional factor for myogenic gene
expression, and is indispensable for MyoD-mediated
muscle differentiation. Knockdown of SET7 impaired the
association of MyoD with the promoter and enhancer re-
gions of the myogenic genes (e.g., Myogenin) and reduced
gene expression by decreasing H3K4me1 levels at itstarget genes. Intriguingly, SET7 antagonizes Suv39h1-
mediated H3-K9 methylation at the myogenic differenti-
ation gene promoters [109].
SMYD1−3
Smyd1 (also called Bop) is essential for mouse cardiac
differentiation [110]. Consistently, knockdown of Smyd1
in zebrafish embryos results in defective skeletal and car-
diac muscle differentiation; this cannot be rescued by
the Smyd1 catalytic mutant, which lacks H3K4 methyl-
transferase activity [21]. SMYD2 methylates H3K4 and
H3K36, as well as tumor-suppressor proteins such as
p53 and Retinoblastoma protein (pRB) [23,111-113].
Specifically, SMYD2-mediated monomethylation of p53
K370 attenuates the interaction of p53 with p53 target
promoters and consequently antagonizes p53-dependent
transcriptional regulation [112]. Unlike SMYD1, cardiac-
specific knockout of Smyd2 has no phenotype during
mouse heart development [114]. SMYD3 is a methyl-
transferase for both H3K4 and H4K5 [15,115]. It is
overexpressed in colorectal and hepatocellular cancers
and promotes cell proliferation [15]. During zebrafish
embryogenesis, SMYD3 appears to be important for car-
diac and skeletal muscle development [116].
SETMAR
SETMAR (also called METNASE) encodes a chimeric
protein that contains an N-terminal SET domain and a
C-terminal mariner transposase domain [117] (Figure 3).
The function of SETMAR in stem cells remains un-
known. However, SETMAR-catalyzed methylation of
H3K4 and H3K36 may lead to an open chromatin struc-
ture, which may facilitate its transposase-dependent pro-
cesses, such as foreign DNA integration and DNA
double-strand break repair [20].
PRDM9
PRDM9 (also called MEISETZ) is a PR/SET domain-
dependent histone methyltransferase that is required for
meiotic prophase progression [18]. Deletion of the
Prdm9 gene attenuates H3K4me3 levels, resulting in de-
fective chromosome pairing, impaired sex body forma-
tion, damaged meiotic progression, and sterility in both
sexes of mice [18]. Mechanistically, Prdm9 binds to
13-base pair DNA elements via its C2H2 zinc fingers.
During early meiosis, this binding event may link
Prdm9-catalyzed H3K4me3 to mammalian meiotic re-
combination hotspots that contain the 13-nucleotide
DNA elements [118-120].
Subunits of H3K4 methyltransferases
WDR5, a core subunit of the SET1 and MLL1−4 com-
plexes, plays an important role in ES cell self-renewal
and somatic cell reprogramming [47]. WDR5 is highly
Figure 3 Protein domain architectures and stem cell function of other H3K4 methyltransferases and core subunits. AT: AT-hook DNA
binding domain; AWS: Associated With SET domain; SET: Su(var)3-9, Enhancer of zeste, Trithorax domain; BRD: Bromodomain; PHD: Plant Homeo
Domain; BAH: Bromo Adjacent Homology domain; MYND: Myeloid, Nervy, and DEAF-1 domain; MT: Mariner Transposase domain; KRAB: Krüppel
Associated Box domain; C2H2: C2H2-type zinc finger; WD: WD40 repeat; SPRY: SplA and Ryanodine domain.
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ation. Knockdown of WDR5 resulted in loss of ES cell
self-renewal and decreased the generation of induced
pluripotent stem cells [47]. WDR5 interacts with OCT4
and activates transcription of the self-renewal factors,
such as OCT4 and NANOG, in ES cells. Moreover,
WDR5, together with OCT4, NANOG and SOX2, regu-
lates the self-renewal-regulatory network [47]. Similarly,
ASH2L is required for the pluripotency of mouse EScells. ASH2L knockdown resulted in elevated expression
of mesodermal lineage differentiation genes [121].
DPY-30 and RBBP5 are other core components of the
SET1/MLL methyltransferases. In contrast to ASH2L
and WDR5, DPY-30 and RBBP5 were not required for
ES cell self-renewal [53]. DPY-30 or RBBP5 knockdown
reduces global and neuronal gene-specific H3K4me3
levels, resulting in inefficient RA-induced neural differ-
entiation of mouse ES cells.
Gu and Lee Cell & Bioscience 2013, 3:39 Page 8 of 14
http://www.cellandbioscience.com/content/3/1/39Differing biological outcomes for ASH2L and WDR5
from DPY-30 and RBBP5 are surprising because these
four proteins are core components of the same SET1/
MLL1−4 methyltransferases. These unexpected findings
might be explained by the following possibilities. Besides
the known SET1/MLL1−4 complexes, some of these
subunits may be present in other complexes in the same
cells so that they may exert different biological functions
from SET1/MLL1−4 complexes. In fact, gel filtration
analysis of ES cell nuclear extracts showed that elution
profiles of WDR5/OCT4 did not overlap with those of
WDR5/ASH2L/RBBP5, suggesting that WDR5 also be-
longs to another new complex containing OCT4 [47].
Another possible scenario is that cellular levels of some
core subunits and H3K4 methyltransferases may be
dynamically changed between ES cells and differen-
tiated cells. Such changes might allow certain H3K4
methyltransferase complexes to be dominant over the
others or lead to formation of new functional complexes,
subsequently affecting expression of stemness genes and
differentiation-specific genes. In support with this, during
ES cell differentiation, ASH2L and WDR5 levels are down-
regulated whereas MLL1 and MLL3 are up-regulated
[47,121]. In addition, some H3K4 methyltransferase
complexes may have non-redundant cellular function
by regulating their unique target genes in a cell type-
specific manner, as mentioned earlier. Future studies
are required to further understand the distinct roles
of the SET1/MLL complexes.
H3K4 demethylases
The reversibility of histone methylation was not clear
until the discovery of the first histone demethylase LSD1
in 2004 [25]. Subsequently, a new class of JmjC-domain-
containing proteins was identified that can demethyl-
ate methylated lysine residues in histones. The F-box
and leucine-rich repeat protein (FBXL11, also known as
KDM2A) is the first identified JmjC domain-containing
demethylase that removes methyl groups from H3K36me2/
1 [122]. The catalytic JmjC domain requires iron and α-
ketoglutarate as cofactors to hydroxylate methyl groups
[123]. Among this class of demethylases, JARID1A−D (or
KDM5A−D) proteins specifically remove the methyl group
from H3K4me2/3. NO66, a bifunctional lysine-specific
demethylase and histidyl-hydroxylase, can demethylate
H3K4me/ H3K36me and hydroxylate a histidyl group of
the non-histone protein Rpl8 [124,125]. Not surprisingly,
the LSD family (LSD1 and LSD2) and JARID1 family of
H3K4 demethylases play important roles in gene transcrip-
tion in stem cell homeostasis.
LSD1 and LSD2
LSD1 protein contains an N-terminal SWIRM domain
and a long C-terminal FAD-dependent amine oxidasedomain (AOD). The AOD is divided by an insertion
known as the tower domain (Figure 4). LSD1 alone
demethylates H3K4me2/1 on histones but not nucleo-
somes, while the association of Co-REST with LSD1 al-
lows LSD1 to demethylate nucleosomal H3K4 [26,27,126].
Numerous studies in ES cells and neural stem cells
strongly suggest that LSD1 is a key histone methyla-
tion modifier in transcriptional regulation for stem cell
fate determination. Lsd1-null mice are embryonic lethal
around E6.5, and Lsd1-deficient mouse ES cells demon-
strate increased cell death and impaired differentiation,
such as embryoid body formation defects [127-129].
Similar to mouse ES cells, LSD1 is required for neural
stem cell proliferation; it is recruited by the nuclear re-
ceptor TLX to repress negative cell cycle regulators,
including p21, in neural stem cells [130]. Interesting-
ly, LSD1 is indispensable for differentiation of several
cell types, including skeletal muscles and adipocytes
[131,132]. In mouse ES cells, LSD1 demethylates and
stabilizes DNA methyltransferase 1 (DNMT1), and Lsd1
deletion results in progressive loss of DNA methylation
[128]. Moreover, LSD1 and its associated nucleosome re-
modeling and histone deacetylase (NuRD) complex are
recruited to Oct4-occupied enhancers at active stemness
genes in ES cells, but the repression activities of LSD1-
NuRD may be antagonized by histone acetyltransferases
(e.g., p300). During mouse ES cell differentiation, Oct4
and acetyltransferase levels are down-regulated, and
LSD1-NuRD decommissions active enhancers by remov-
ing H3K4me1 while promoting cellular differentiation
[45]. In contrast to the above stem cell studies, seem-
ingly conflicting results regarding the role of LSD1 in ES
cells have been reported. Knockdown of LSD1 induces
differentiation in human ES cells, which is correlated
with de-repression of developmental genes with elevated
H3K4me2/3 levels [44]. In addition, Lsd1−/− ES cells had
a strong potential to generate extraembryonic tissues
from the embryoid body [133].
LSD2 (AOF1 or KDM1B) was recently identified
as a homolog of LSD1; it demethylates H3K4me2/1
like LSD1 [28,134-136]. Interestingly, unlike LSD1,
LSD2 has no tower domain in the AOD region, but con-
tains unique N-terminal zinc fingers, including C4H2C2
and CW-type zinc fingers, which are required for
demethylase activity [136,137] (Figure 4). A genome-
wide mapping analysis revealed that LSD2 primarily
resides in the intragenic regions of actively expressed
genes [28]. LSD2 may activate its target genes, possibly
via its association with transcriptional elongation factors
[28]. Lsd2 is not essential for mouse development. How-
ever, the DNA methylation of several imprinted genes is
lost in oocytes from lsd2-deleted females [135]. Conse-
quently, the embryos derived from these oocytes
exhibited biallelic expression or silencing (i.e., loss of
Figure 4 Protein domain architectures and stem cell function of H3K4 demethylases. SWIRM: SWI3, RSC8 and MOIRA domain; AOD-N:
Amine Oxidase Domain-N terminal; TOWER: LSD1 tower domain; AOD-C: Amine Oxidase Domain-C terminal; C4H2C2: C4H2C2-type zinc finger;
ZF_CW: CW-type zinc finger; AOD: Amine Oxidase Domain; JmjN: Jumonji N domain; ARID: AT-rich interactive domain; PHD: Plant Homeo
Domain; JmjC: Jumonji C domain; C5HC2: C5HC2-type zinc finger.
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and died before mid-gestation [135]. The molecular
mechanism underlying the functional link between H3K4
demethylation and DNA methylation for expression of
imprinted genes remains to be investigated.
JARID1A
JARID1A (RBP2 or KDM5A) was identified as a binding
partner of pRB protein in early 1990 [138]. RBP2 con-
tains a highly conserved JmjC domain and was found as
a specific H3K4me3/2 demethylase [30,139] (Figure 4).
Rbp2−/− mice are viable and display mild phenotypic de-
fects in expansion of hematopoietic stem cells and mye-
loid progenitors. The weak phenotype of Rbp2−/− mice
suggests that other JARID1 family proteins may compen-
sate the loss of Rbp2 [139].
During ES cell differentiation, RBP2 is dissociated from
HOX genes, resulting in increased H3K4me3 levels and
gene activation [30]. Consistently, Pasini et al. reported
that RBP2 associates with the important Polycombrepressive complex 2 (PRC2), which enzymatically gener-
ates the repressive mark H3K27me3 for silencing of many
differentiation-specific genes in ES cells [140]. A genome-
wide chromatin immunoprecipitation (ChIP)-on-chip ana-
lysis revealed that RBP2 colocalizes on a subset of PRC2
target gene promoters in mouse ES cells. However, the
interaction of RBP2 with PRC2 may not be strong, be-
cause the mass spectrometric analysis revealed that affinity
eluates of the PRC2 component EED, which were purified
from ES cell extracts, did not contain RBP2 [141]. Beshiri
et al. recently demonstrated that RBP2 augments the re-
pressive effects of the pRB-related protein p130 and E2F4
on cell cycle genes during stem cell differentiation via
H3K4me3 demethylation [142]. Interestingly, RBP2 in-
hibits osteogenic differentiation of human adipose-derived
stroma cells [143]. RBP2 interacts with Runt-related tran-
scription factor 2 (RUNX2), a transcriptional factor that
is required for osteogenic differentiation. Subsequently,
RBP2 represses RUNX2 target genes, including Alkaline
phosphatase, Osteocalcin, and Osterix [143].
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JARID1B (PLU1 or KDM5B) was shown to be over-
expressed in breast cancer cell lines [144]. As a member
of the JARID1 family, PLU1 catalyzes the demethylation
of H3K4me2/3. Its full activity requires JmjN, ARID,
PHD1, and C5HC2 zinc finger in addition to the catalytic
domain JmjC [30,34] (Figure 4). Consistent with the re-
sult of earlier studies, knockdown of PLU1 reduced
MCF7 breast cancer cell proliferation and concomitantly
upregulated expression of the Breast cancer1, early onset
(BRCA1), Caveolin 1 (CAV1), and HOXA5 genes as a re-
sult of increased H3K4me3 levels on their promoters
[34]. However, PLU1′s role in ES cell self-renewal and
differentiation is controversial. Xie et al. reported that
PLU1 is a downstream target of the pluripotent factor
Nanog and is required for ES cell self-renewal [145].
PLU1 interacts with the chromodomain protein MRG15
and is recruited to H3K36me3-containing sites within
gene bodies of self-renewal-associated genes via MRG15.
Knockdown of PLU1 or MRG15 increased intragenic
H3K4me3 that produces cryptic intragenic transcription
and inhibited the transcriptional elongation [145]. An-
other study showed that constitutive overexpression of
PLU1 blocked neural terminal differentiation [146]. On
the contrary, Schmitz et al. has provided evidence that
PLU1 is required for the neural differentiation of ES
cells but is dispensable for self-renewal [147]. Using a
genome-wide ChIP-sequencing analysis, they found that
PLU1 predominantly localizes on the transcription start
sites of target genes, over 50% of which are also occu-
pied by Polycomb group proteins. PLU1-depleted ES
cells fail to differentiate into the neural lineage, which
correlates with the inappropriate depression of stem and
germ cell genes [147]. These findings are further sup-
ported by their recent research in Plu1 knockout mice,
which have the phenotype of neonatal lethality and
neural defects [148]. The discrepancies in these studies
regarding the role of PLU1 in ES cell homeostasis are
not entirely clear. However, Schmitz et al. indicated that
their PLU1 localization data were obtained using a better
PLU1 antibody and that the unimportance of PLU1 in
ES cell self-renewal was confirmed by both a lentiviral
shRNA knockdown method and a genetic deletion
approach.
JARID1C and JARID1D
Compared with RBP2 and PLU1, much less is known
about the biological function of JARID1C (SMCX or
KDM5C) and JARID1D (SMCY or KDM5D). Both
demethylases have similar domain structures and con-
tain a conserved and functional JmjC domain that is re-
sponsible for demethylating H3K4me2/3 [30-32]. SMCX
is an X-chromosome gene that escapes from X inacti-
vation [149] and is often mutated in renal tumorsand X-linked mental retardation (XLMR), suggesting that
it has important functions in the human kidneys and brain
[150,151]. Indeed, SMCX is highly expressed in brain dur-
ing zebrafish development and is required for neuron sur-
vival [31]. Moreover, SMCX knockdown reduces dendritic
length of rat primary neurons, which cannot be rescued
by its XLMR-patient mutants with reduced demethylase
activity [31]. Therefore, SMCX may play an important role
in neuronal development. In addition, Outchkourov et al.
reported that SMCX may interact with the transcriptional
factors c-MYC and ELK1 to regulate gene expression in
mouse ES cells [152].
JARID1D requires multiple domains, including ARID,
JmjC, and C5HC2 zinc finger, for its full demethylase ac-
tivity towards H3K4me3/2 [32] (Figure 4). JARID1D in-
teracts with RING6A/MBLR, a polycomb-like protein
with homology to Mel18 and Bmi1 proteins [153]. This
interaction stimulates JARID1D’s enzyme activity in vitro;
the protein complex mediates H3K4me3 demethylation at
the Engrailed 2 gene promoter and is required for
Engrailed 2 gene repression [32]. However, JARID1D’s bio-
logical role in stem cells is largely unknown. Given its
localization on the Y-chromosome, it will be interesting to
determine whether JARID1D plays a role in male-specific
gene expression in vivo.
NO66
NO66 has been reported to demethylate H3K4me3/2/1
and H3K36me3/2 [124] and to catalyze histidyl hydroxyl-
ation of the 60S ribosomal protein Rpl8 [125]. This en-
zyme inhibits osteoblast differentiation [124]. Specifically,
it directly interacts with Osterix, an osteoblast-specific
transcription factor, and represses Osterix target gene ex-
pression [124]. In addition, NO66 plays a role in mouse
ES cell differentiation [154]. During this process, it is
recruited to stemness genes (e.g., Oct4 and Nanog) via the
PHD finger protein 19 (PHF19), which interacts with the
H3K27 methyltransferase complex PRC2; NO66-PHF19-
PRC2 represses gene expression by reducing H3K36me3
and increasing H3K27me3 [154].
Conclusions
Stem cells are indistinguishable from somatic cells at the
genomic level. In contrast, there are remarkable differ-
ences in epigenomes that may be represented by cova-
lent and noncovalent modifications of histones and
DNA. As reviewed herein, specific epigenetic modifiers,
such as H3K4 methylation modifiers, may play funda-
mental roles in orchestrating cellular epigenomes whose
genomic sequences are identical. Consistent with this,
many H3K4 methylation modifiers and their components
are required for ES cell self-renewal or differentiation.
In addition, some of them cooperate with transcription
factors for efficient somatic cell reprogramming. For
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pluripotent stem cells that were induced by Oct4, Sox2,
c-Myc, and Klf4 [47]. Therefore, the epigenetic modi-
fiers, with the transcription factor network, may establish
epigenomes in a coordinate manner.
Recently, small molecule inhibitors against specific
histone methyltransferases, including LSD1 inhibitors,
have been developed by several pharmaceutical compan-
ies, although their specificities and efficacies require im-
provement [155]. Certain inhibitors, alone or combined,
may increase somatic reprogramming efficiency or drive
somatic reprogramming, perhaps providing new avenues
for personalized therapeutic interventions using stem
cells. With regard to the roles of histone modifiers in
stem cell maintenance and differentiation, many more
new exciting findings are expected. We predict that
our current and future knowledge about stem cell self-
renewal and lineage commitment will be highly relevant
to cancer stem cell studies, because stem cells and can-
cer stem cells share several characteristics, such as high
degrees of self-renewal and differentiation [156]. We be-
lieve that a new era of stem cell epigenetics has begun.
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